http://dev1.sol.com.au/paper/ 2025-08-01T07:12:01+00:00 http://dev1.sol.com.au/paper/confocal-microscopy-dermoscopy-and-histopathology-features-of-atypical-intraepidermal-melanocytic-proliferations-associated-with-evolution-to-melanoma-in-situ/ 2022-05-16T06:27:08+00:00 http://dev1.sol.com.au/paper/survival-outcomes-of-salvage-metastasectomy-after-failure-of-modern-era-systemic-therapy-for-melanoma/ 2022-05-16T06:29:17+00:00 http://dev1.sol.com.au/paper/pathological-response-and-survival-with-neoadjuvant-therapy-in-melanoma-a-pooled-analysis-from-the-international-neoadjuvant-melanoma-consortium-inmc/ 2022-06-09T00:58:09+00:00 http://dev1.sol.com.au/paper/high-dimensional-single-cell-transcriptomics-in-melanoma-and-cancer-immunotherapy/ 2022-07-23T06:19:32+00:00 http://dev1.sol.com.au/paper/review-braf-inhibition-and-the-spectrum-of-granulomatous-reactions/ 2022-07-23T06:23:30+00:00 http://dev1.sol.com.au/paper/antitumor-activity-of-ipilimumab-or-braf-%c2%b1-mek-inhibition-after-pembrolizumab-in-patients-with-advanced-melanoma-analysis-from-keynote-006/ 2022-07-23T06:27:18+00:00 http://dev1.sol.com.au/paper/complex-melanoma-of-the-scalp-diagnosis-and-management-aided-by-confocal-microscopy/ 2022-07-23T06:32:33+00:00 http://dev1.sol.com.au/paper/repurposing-melanoma-chemotherapy-to-activate-inflammasomes-in-the-treatment-of-braf-mapk-inhibitor-resistant-melanoma/ 2022-07-23T06:39:59+00:00 http://dev1.sol.com.au/paper/grade-4-neutropenia-secondary-to-immune-checkpoint-inhibition-a-descriptive-observational-retrospective-multicenter-analysis/ 2022-07-23T06:44:16+00:00 http://dev1.sol.com.au/paper/acute-bilateral-phrenic-nerve-neuropathy-causing-hypercapnic-respiratory-associated-with-checkpoint-inhibitor-immunotherapy/ 2022-07-23T06:47:19+00:00 http://dev1.sol.com.au/paper/case-report-of-a-challenging-medium-sized-congenital-melanocytic-nevus-cmn-highlighting-a-role-for-reflectance-confocal-microscopy-rcm-for-evaluating-changing-cmn-in-children/ 2022-07-23T06:50:47+00:00 http://dev1.sol.com.au/paper/association-between-melanoma-detected-during-routine-skin-checks-and-mortality/ 2022-07-23T06:56:23+00:00 http://dev1.sol.com.au/paper/optical-coherence-tomography-features-of-a-tumour-of-the-follicular-infundibulum/ 2022-07-23T07:04:44+00:00 http://dev1.sol.com.au/paper/optical-coherence-tomography-features-of-a-tumour-of-the-follicular-infundibulum-2/ 2022-07-23T07:10:03+00:00 http://dev1.sol.com.au/paper/long-term-outcomes-with-nivolumab-plus-ipilimumab-or-nivolumab-alone-versus-ipilimumab-in-patients-with-advanced-melanoma/ 2022-07-23T07:15:22+00:00 http://dev1.sol.com.au/paper/assessing-the-potential-for-patient-led-surveillance-after-treatment-of-localized-melanoma-mel-self-a-pilot-randomized-clinical-trial/ 2022-07-23T07:22:11+00:00 http://dev1.sol.com.au/paper/multi-trait-genetic-analysis-identifies-auto-immune-loci-associated-with-cutaneous-melanoma/ 2022-07-23T07:26:41+00:00 http://dev1.sol.com.au/paper/adaptive-designs-for-clinical-trials-have-potential-advantages-but-statistical-challenges-lurk/ 2022-07-23T07:31:02+00:00 http://dev1.sol.com.au/paper/unravelling-checkpoint-inhibitor-associated-autoimmune-diabetes-from-bench-to-bedside/ 2022-07-23T07:34:37+00:00 http://dev1.sol.com.au/paper/impact-of-next-generation-sequencing-on-interobserver-agreement-and-diagnosis-of-spitzoid-neoplasms/ 2022-07-23T07:39:25+00:00 http://dev1.sol.com.au/paper/a-survey-of-surgical-management-of-the-sentinel-node-positive-melanoma-patient-in-the-post-mslt2-era/ 2022-07-23T07:42:30+00:00 http://dev1.sol.com.au/paper/the-concepts-of-rechallenge-and-retreatment-with-immune-checkpoint-blockade-in-melanoma-patients/ 2022-07-23T08:20:00+00:00 http://dev1.sol.com.au/paper/tmb-and-inflammatory-gene-expression-associated-with-clinical-outcomes-following-immunotherapy-in-advanced-melanoma/ 2022-07-23T08:25:33+00:00 http://dev1.sol.com.au/paper/impact-of-personal-genomic-risk-information-on-melanoma-prevention-behaviors-and-psychological-outcomes-a-randomized-controlled-trial/ 2022-07-23T08:31:09+00:00 http://dev1.sol.com.au/paper/survival-outcomes-of-salvage-metastasectomy-after-failure-of-modern-era-systemic-therapy-for-melanoma-2/ 2022-07-23T08:38:50+00:00 http://dev1.sol.com.au/paper/early-use-of-high-dose-glucocorticoid-for-the-management-of-irae-is-associated-with-poorer-survival-in-patients-with-advanced-melanoma-treated-with-anti-pd-1-monotherapy/ 2022-07-23T08:42:02+00:00 http://dev1.sol.com.au/paper/aso-author-reflections-surgical-resection-may-improve-the-outcome-for-patients-with-residual-metastatic-melanoma-when-modern-systemic-therapies-have-not-achieved-complete-disease-control/ 2022-07-23T08:45:23+00:00 http://dev1.sol.com.au/paper/ipilimumab-versus-ipilimumab-plus-anti-pd-1-for-metastatic-melanoma-authors-reply/ 2022-07-23T08:49:18+00:00 http://dev1.sol.com.au/paper/a-survey-of-surgical-management-of-the-sentinel-node-positive-melanoma-patient-in-the-post-mslt2-era-2/ 2022-07-23T08:54:18+00:00 http://dev1.sol.com.au/paper/strengthening-melanoma-prevention-and-early-detection-among-people-with-type-2-diabetes/ 2022-07-23T08:56:44+00:00 http://dev1.sol.com.au/paper/residual-melanoma-in-wide-local-excision-specimens-after-complete-excision-of-primary-cutaneous-in-situ-and-invasive-melanomas/ 2022-07-23T08:59:17+00:00 http://dev1.sol.com.au/paper/metastatic-acral-melanoma-treatment-outcomes-a-systematic-review-and-meta-analysis/ 2022-07-23T09:06:20+00:00 http://dev1.sol.com.au/paper/position-statement-on-classification-of-basal-cell-carcinomas-part-1-unsupervised-clustering-of-experts-as-a-way-to-build-an-operational-classification-of-advanced-basal-cell-carcinoma-based-on-patt/ 2022-07-23T09:11:07+00:00 http://dev1.sol.com.au/paper/position-statement-on-classification-of-basal-cell-carcinomas-part-2-eado-proposal-for-new-operational-staging-system-adapted-to-basal-cell-carcinomas/ 2022-07-23T09:14:13+00:00 http://dev1.sol.com.au/paper/cutaneous-clear-cell-sarcoma-with-an-epidermal-component-mimicking-melanoma/ 2022-07-23T09:17:56+00:00 http://dev1.sol.com.au/paper/skin-cancer-classification-via-convolutional-neural-networks-systematic-review-of-studies-involving-human-experts/ 2022-07-23T09:23:39+00:00 http://dev1.sol.com.au/paper/adjuvant-immunotherapy-recommendations-for-stage-iii-melanoma-physician-and-nurse-interviews/ 2022-07-23T09:30:18+00:00 http://dev1.sol.com.au/paper/interleukin-6-blockade-for-prophylaxis-and-management-of-immune-related-adverse-events-in-cancer-immunotherapy/ 2022-07-23T09:38:03+00:00 http://dev1.sol.com.au/paper/a-practical-guide-on-the-use-of-imiquimod-cream-for-lentigo-maligna/ 2022-07-23T09:40:49+00:00 http://dev1.sol.com.au/paper/immune-checkpoint-inhibitors-in-melanoma/ 2022-07-23T09:51:12+00:00 http://dev1.sol.com.au/paper/parp-inhibitors-in-melanoma-an-expanding-therapeutic-option/ 2022-07-23T09:56:37+00:00 http://dev1.sol.com.au/paper/irregular-sleep-wake-patterns-are-associated-with-reduced-quality-of-life-in-post-treatment-cancer-patients-a-study-across-three-cancer-cohorts/ 2022-07-23T10:03:08+00:00 http://dev1.sol.com.au/paper/long-term-outcomes-in-patients-with-advanced-melanoma-who-had-initial-stable-disease-with-pembrolizumab-in-keynote-001-and-keynote-006/ 2022-07-23T10:08:01+00:00 http://dev1.sol.com.au/paper/road-to-metastasis-the-tweak-pathway-as-a-discriminant-between-metastasizing-and-non-metastasizing-thick-melanomas/ 2022-07-23T10:16:25+00:00 http://dev1.sol.com.au/paper/melanoma-brain-metastases-that-progress-on-braf-mek-inhibitors-demonstrate-resistance-to-ipilimumab-nivolumab-that-is-associated-with-the-innate-pd-1-resistance-signature-ipres/ 2022-07-23T10:20:49+00:00 http://dev1.sol.com.au/paper/combined-presentation-and-immunogenicity-analysis-reveals-a-recurrent-ras-q61k-neoantigen-in-melanoma/ 2022-07-23T10:29:32+00:00 http://dev1.sol.com.au/paper/interventions-to-increase-sunscreen-use-in-adults-a-review-of-the-literature/ 2022-07-23T10:32:51+00:00 http://dev1.sol.com.au/paper/immune-checkpoint-inhibitors-in-patients-with-pre-existing-psoriasis-safety-and-efficacy/ 2022-07-23T10:38:01+00:00 http://dev1.sol.com.au/paper/deep-learning-for-basal-cell-carcinoma-detection-for-reflectance-confocal-microscopy/ 2022-07-23T10:42:26+00:00 http://dev1.sol.com.au/paper/surveillance-of-patients-with-thin-melanoma/ 2022-07-23T10:46:53+00:00 http://dev1.sol.com.au/paper/contemporary-management-of-locoregionally-advanced-melanoma-in-australia-and-new-zealand-and-the-role-of-adjuvant-systemic-therapy/ 2022-07-23T10:52:26+00:00 http://dev1.sol.com.au/paper/a-multicentre-study-of-naevus-associated-melanoma-vs-de-novo-melanoma-tumour-thickness-and-body-site-differences/ 2022-07-23T10:56:30+00:00 http://dev1.sol.com.au/paper/melanoma-in-situ-a-critical-review-and-re-evaluation-of-current-excision-margin-recommendations/ 2022-07-23T10:59:19+00:00 http://dev1.sol.com.au/paper/in-sentinel-node-positive-melanoma-patients-does-omission-of-completion-lymph-node-dissection-make-more-intensive-follow-up-necessary-and-does-adjuvant-systemic-therapy-permit-less-intensive-follow/ 2022-07-23T11:02:51+00:00 http://dev1.sol.com.au/paper/correction-to-histological-regression-in-melanoma-impact-on-sentinel-lymph-node-status-and-survival/ 2022-07-23T11:07:37+00:00 http://dev1.sol.com.au/paper/knowledge-views-and-expectations-for-cancer-polygenic-risk-testing-in-clinical-practice-a-cross-sectional-survey-of-health-professionals/ 2022-07-23T11:11:35+00:00 http://dev1.sol.com.au/paper/standard-dose-pembrolizumab-plus-alternate-dose-ipilimumab-in-advanced-melanoma-keynote-029-cohort-1c-a-phase-2-randomized-study-of-two-dosing-schedules/ 2022-07-23T11:15:41+00:00 http://dev1.sol.com.au/paper/histological-regression-in-melanoma-impact-on-sentinel-lymph-node-status-and-survival/ 2022-07-23T11:19:27+00:00 http://dev1.sol.com.au/paper/pyrexia-in-patients-treated-with-dabrafenib-plus-trametinib-across-clinical-trials-in-braf-mutant-cancers/ 2022-07-23T11:22:36+00:00 http://dev1.sol.com.au/paper/validation-of-the-american-joint-committee-on-cancer-staging-in-squamous-cell-carcinoma-of-the-vermilion-lip/ 2022-07-23T11:26:14+00:00 http://dev1.sol.com.au/paper/melanoma-with-osseous-or-chondroid-differentiation-a-report-of-eight-cases-including-satb2-expression-and-mutation-analysis/ 2022-07-23T11:30:04+00:00 http://dev1.sol.com.au/paper/neoadjuvant-immunotherapy-in-melanoma-the-new-frontier/ 2022-07-23T11:34:18+00:00 http://dev1.sol.com.au/paper/counting-mitoses-size-matters/ 2022-07-23T11:39:14+00:00 http://dev1.sol.com.au/paper/evaluation-of-crizotinib-treatment-in-a-patient-with-unresectable-gopc-ros1-fusion-agminated-spitz-nevi/ 2022-07-23T11:43:01+00:00 http://dev1.sol.com.au/paper/neoadjuvant-immunotherapy-in-melanoma-the-new-frontier-2/ 2022-07-23T11:46:48+00:00 http://dev1.sol.com.au/paper/current-challenges-in-access-to-melanoma-care-a-multidisciplinary-perspective/ 2022-07-23T11:53:30+00:00 http://dev1.sol.com.au/paper/risk-of-radiation-necrosis-after-stereotactic-radiosurgery-for-melanoma-brain-metastasis-by-anatomical-location/ 2022-07-23T11:57:15+00:00 http://dev1.sol.com.au/paper/role-of-tumor-infiltrating-b-cells-in-clinical-outcome-of-patients-with-melanoma-treated-with-dabrafenib-plus-trametinib/ 2022-07-23T12:00:01+00:00 http://dev1.sol.com.au/paper/risk-factors-for-melanoma-by-anatomical-site-an-evaluation-of-aetiological-heterogeneity/ 2022-07-23T12:03:24+00:00 http://dev1.sol.com.au/paper/pdcd1-polymorphisms-may-predict-response-to-anti-pd-1-blockade-in-patients-with-metastatic-melanoma/ 2022-07-25T11:10:57+00:00 http://dev1.sol.com.au/paper/pembrolizumab-versus-placebo-as-adjuvant-therapy-stageii-melanoma-keynote-716/ 2022-07-25T11:12:03+00:00 http://dev1.sol.com.au/paper/evolutionary-predictability-of-genetic-versus-nongenetic-resistance-to-anticancer-drugs-in-melanoma/ 2022-07-25T11:14:53+00:00 http://dev1.sol.com.au/paper/re-defining-the-role-of-surgery-in-the-management-of-patients-with-oligometastatic-stage-iv-melanoma-in-the-era-of-effective-systemic-therapies/ 2022-07-25T11:21:25+00:00 http://dev1.sol.com.au/paper/bilateral-facial-neuritis-associated-with-dabrafenib-and-trametinib-after-failure-of-neoadjuvant-immunotherapy-for-stage-iii-melanoma/ 2022-07-25T11:24:51+00:00 http://dev1.sol.com.au/paper/lysine-demethylases-promising-drug-targets-in-melanoma-and-other-cancers/ 2022-07-25T11:27:36+00:00 http://dev1.sol.com.au/paper/identifying-the-active-ingredients-of-an-effective-psychological-intervention-to-reduce-fear-of-cancer-recurrence-a-process-evaluation/ 2022-07-25T11:31:38+00:00 http://dev1.sol.com.au/paper/hyperacute-toxicity-with-combination-ipilimumab-and-anti-pd1-immunotherapy/ 2022-07-25T11:35:49+00:00 http://dev1.sol.com.au/paper/re-induction-ipilimumab-following-acquired-resistance-to-combination-ipilimumab-and-anti-pd-1-therapy/ 2022-07-25T11:40:02+00:00 http://dev1.sol.com.au/paper/clinical-and-molecular-heterogeneity-in-patients-with-innate-resistance-to-anti-pd-1-anti-ctla-4-immunotherapy-in-metastatic-melanoma-reveals-distinct-therapeutic-targets/ 2022-07-25T11:44:37+00:00 http://dev1.sol.com.au/paper/characterizing-the-clinical-implications-of-histologic-regression-in-melanoma-requires-clear-diagnostic-criteria-that-are-consistently-applied-reply/ 2022-07-25T11:47:59+00:00 http://dev1.sol.com.au/paper/immunotherapy-in-advanced-merkel-cell-carcinoma-sydney-west-cancer-network-experience/ 2022-07-25T11:50:40+00:00 http://dev1.sol.com.au/paper/melanoma-in-situ-a-critical-review-and-re-evaluation-of-current-excision-margin-recommendations-2/ 2022-07-25T11:52:45+00:00 http://dev1.sol.com.au/paper/predicting-recurrence-in-patients-with-sentinel-node-negative-melanoma-validation-of-the-eortc-nomogram-using-population-based-data/ 2022-07-25T12:03:57+00:00 http://dev1.sol.com.au/paper/the-role-of-regional-chemotherapy-for-advanced-limb-melanoma-in-the-era-of-potentially-effective-systemic-therapies/ 2022-07-25T12:06:08+00:00 http://dev1.sol.com.au/paper/changes-in-sun-protection-behaviours-sun-exposure-and-shade-availability-among-adults-children-and-adolescents-in-new-south-wales-2003-2016/ 2022-07-25T12:08:51+00:00 http://dev1.sol.com.au/paper/melanoma-cell-state-specific-responses-to-tnf%ce%b1/ 2022-07-25T12:10:49+00:00 http://dev1.sol.com.au/paper/an-independent-external-validation-of-melanoma-risk-prediction-models-using-the-australian-melanoma-family-study/ 2022-07-25T12:14:15+00:00 http://dev1.sol.com.au/paper/melanoma-recurrence-patterns-and-management-after-adjuvant-targeted-therapy-a-multicentre-analysis/ 2022-07-25T12:17:12+00:00 http://dev1.sol.com.au/paper/comparative-genomics-provides-etiological-and-biological-insights-into-melanoma-subtypes/ 2022-10-09T10:35:02+00:00 http://dev1.sol.com.au/paper/unveiling-the-tumor-immune-microenvironment-of-organ-specific-melanoma-metastatic-sites/ 2022-10-09T10:38:54+00:00 http://dev1.sol.com.au/paper/views-of-the-australian-public-on-the-delivery-of-risk-stratified-cancer-screening-in-the-population-a-qualitative-study/ 2022-10-09T10:40:00+00:00 http://dev1.sol.com.au/paper/higher-polygenic-risk-for-melanoma-is-associated-with-improved-survival-in-a-high-ultraviolet-radiation-setting/ 2022-10-09T10:41:43+00:00 http://dev1.sol.com.au/paper/developing-an-australian-melanoma-clinical-outcomes-registry-melcor-a-protocol-paper/ 2022-10-09T10:42:39+00:00 http://dev1.sol.com.au/paper/keynote-d36-personalized-immunotherapy-with-a-neoepitope-vaccine-evx-01-and-pembrolizumab-in-advanced-melanoma/ 2022-10-09T10:43:26+00:00 http://dev1.sol.com.au/paper/assessing-the-value-of-precision-medicine-health-technologies-to-detect-and-manage-melanoma/ 2022-10-10T10:52:53+00:00 http://dev1.sol.com.au/paper/in-vivo-tumor-immune-microenvironment-phenotypes-correlate-with-inflammation-and-vasculature-to-predict-immunotherapy-response/ 2022-10-23T08:14:26+00:00 http://dev1.sol.com.au/paper/phase-ib-ii-trial-of-ribociclib-in-combination-with-binimetinib-in-patients-with-nras-mutant-melanoma/ 2022-10-23T08:41:23+00:00 http://dev1.sol.com.au/paper/diet-driven-microbial-ecology-underpins-associations-between-cancer-immunotherapy-outcomes-and-the-gut-microbiome/ 2022-10-23T08:53:17+00:00 http://dev1.sol.com.au/paper/utility-of-optical-coherence-tomography-in-basal-cell-naevus-syndrome-a-case-report/ 2022-10-23T08:56:19+00:00 http://dev1.sol.com.au/paper/navigating-the-cellular-landscape-in-tissue-recent-advances-in-defining-the-pathogenesis-of-human-disease/ 2022-10-23T08:59:56+00:00 http://dev1.sol.com.au/paper/five-year-analysis-of-adjuvant-pembrolizumab-or-placebo-in-stage-iii-melanoma/ 2022-10-23T09:07:40+00:00 http://dev1.sol.com.au/paper/survival-outcomes-of-perineural-spread-in-head-and-neck-cutaneous-squamous-cell-carcinoma/ 2022-10-23T09:13:59+00:00 http://dev1.sol.com.au/paper/high-dimensional-and-spatial-analysis-reveals-immune-landscape-dependent-progression-in-cutaneous-squamous-cell-carcinoma/ 2022-10-23T09:17:17+00:00 http://dev1.sol.com.au/paper/whole-genome-analysis-reveals-the-genomic-complexity-in-metastatic-cutaneous-squamous-cell-carcinoma/ 2022-10-23T09:21:48+00:00 http://dev1.sol.com.au/paper/protein-based-classification-of-melanoma-differentiation-subtypes/ 2022-10-23T09:24:48+00:00 http://dev1.sol.com.au/paper/outcomes-after-definitive-treatment-for-head-and-neck-angiosarcoma/ 2022-10-23T09:28:59+00:00 http://dev1.sol.com.au/paper/benchmarking-survival-outcomes-following-surgical-management-of-pt3-and-pt4-cutaneous-squamous-cell-carcinoma-of-the-head-and-neck/ 2022-10-23T09:57:14+00:00 http://dev1.sol.com.au/paper/repurposing-melanoma-chemotherapy-to-activate-inflammasomes-in-the-treatment-of-braf-mapk-inhibitor-resistant-melanoma-2/ 2022-10-23T10:01:03+00:00 http://dev1.sol.com.au/paper/mhc-class-i-deficiency-in-solid-tumors-and-therapeutic-strategies-to-overcome-it/ 2022-10-23T10:04:26+00:00 http://dev1.sol.com.au/paper/distinct-immune-cell-populations-define-response-to-anti-pd-1-monotherapy-and-anti-pd-1-anti-ctla-4-combined-therapy/ 2022-11-08T23:00:00+00:00 http://dev1.sol.com.au/paper/communicating-personal-melanoma-polygenic-risk-information-participants-experiences-of-genetic-counseling-in-a-community-based-study/ 2022-11-19T10:54:58+00:00 http://dev1.sol.com.au/paper/feasibility-acceptability-and-utility-of-a-nurse-led-survivorship-program-for-people-with-metastatic-melanoma-melcare/ 2022-11-19T10:55:24+00:00 http://dev1.sol.com.au/paper/neurological-adverse-effects-associated-with-anti-pd1-antibodies-alone-or-in-combination-with-ipilimumab-a-multicenter-case-series/ 2022-11-19T11:01:59+00:00 http://dev1.sol.com.au/paper/validation-of-self-reported-sun-exposure-against-electronic-ultraviolet-radiation-dosimeters/ 2022-11-19T11:02:54+00:00 http://dev1.sol.com.au/paper/recursive-partitioning-to-determine-order-of-significance-of-regional-metastasis-characteristics-in-head-and-neck-cutaneous-squamous-cell-carcinoma/ 2022-11-19T11:04:45+00:00 http://dev1.sol.com.au/paper/adjuvant-therapy-of-nivolumab-combined-with-ipilimumab-versus-nivolumab-alone-in-patients-with-resected-stage-iiib-d-or-stage-iv-melanoma-checkmate-915/ 2022-11-19T11:17:24+00:00 http://dev1.sol.com.au/paper/obesity-is-associated-with-altered-tumor-metabolism-in-metastatic-melanoma/ 2022-11-19T11:24:52+00:00 http://dev1.sol.com.au/paper/hypoxia-controls-the-glycome-signature-and-galectin-8-ligand-axis-to-promote-pro-tumorigenic-properties-of-metastatic-melanoma/ 2022-11-19T11:31:02+00:00 http://dev1.sol.com.au/paper/characteristics-of-immune-checkpoint-inhibitor-induced-encephalitis-and-comparison-with-hsv-1-and-anti-lgi1-encephalitis-a-retrospective-multicentre-cohort-study/ 2022-11-19T11:37:15+00:00 http://dev1.sol.com.au/paper/adjuvant-pembrolizumab-versus-placebo-in-resected-high-risk-stage-ii-melanoma-health-related-quality-of-life-from-the-randomized-phase-3-keynote-716-study/ 2022-11-19T11:44:45+00:00 http://dev1.sol.com.au/paper/motivations-and-barriers-to-participation-in-a-randomized-trial-on-melanoma-genomic-risk-a-mixed-methods-analysis/ 2022-11-19T22:08:20+00:00 http://dev1.sol.com.au/paper/causes-consequences-and-clinical-significance-of-aneuploidy-across-melanoma-subtypes/ 2022-11-19T22:15:44+00:00 http://dev1.sol.com.au/paper/factors-influencing-acceptance-adoption-and-adherence-to-sentinel-node-biopsy-recommendations-in-the-australian-melanoma-management-guidelines-a-qualitative-study-using-an-implementation-science-fra/ 2022-11-19T22:22:58+00:00 http://dev1.sol.com.au/paper/is-a-history-of-optimal-staging-by-sentinel-lymph-node-biopsy-in-the-era-prior-to-adjuvant-therapy-associated-with-improved-outcome-once-melanoma-patients-have-progressed-to-advanced-disease/ 2022-11-19T22:27:24+00:00 http://dev1.sol.com.au/paper/exploring-the-integration-of-environmental-impacts-in-the-cost-analysis-of-the-pilot-mel-self-trial-of-patient-led-melanoma-surveillance/ 2022-11-19T22:34:27+00:00 http://dev1.sol.com.au/paper/pembrolizumab-versus-placebo-as-adjuvant-therapy-in-resected-stage-iib-or-iic-melanoma-keynote-716-distant-metastasis-free-survival-results-of-a-multicentre-double-blind-randomised-phase-3-trial/ 2022-11-19T22:47:33+00:00 http://dev1.sol.com.au/paper/clinical-management-of-melanocytic-tumours-of-uncertain-malignant-potential-meltumps-including-melanocytomas-a-systematic-review-and-meta-analysis/ 2022-11-19T23:15:57+00:00 http://dev1.sol.com.au/paper/dataset-for-the-reporting-of-merkel-cell-carcinoma-recommendations-from-the-international-collaboration-on-cancer-reporting-iccr/ 2022-11-19T23:22:19+00:00 http://dev1.sol.com.au/paper/diagnosis-and-treatment-of-merkel-cell-carcinoma-european-consensus-based-interdisciplinary-guideline-update-2022/ 2022-11-19T23:26:50+00:00 http://dev1.sol.com.au/paper/aso-visual-abstract-predictors-of-sentinel-lymph-node-metastasis-in-patients-with-thin-melanoma-an-international-multi-institutional-collaboration/ 2022-11-19T23:33:10+00:00 http://dev1.sol.com.au/paper/real-world-outcomes-with-ipilimumab-and-nivolumab-in-advanced-melanoma-a-multicentre-retrospective-study/ 2022-11-20T02:34:01+00:00 http://dev1.sol.com.au/paper/neoadjuvant-nivolumab-t-vec-combination-therapy-for-resectable-early-stage-or-metastatic-iiib-ivm1a-melanoma-with-injectable-disease-study-protocol-of-the-nivec-trial/ 2022-11-20T02:34:53+00:00 http://dev1.sol.com.au/paper/nicotinamide-inhibits-t-cell-exhaustion-and-increases-differentiation-of-cd8-effector-t-cells/ 2022-11-20T02:43:47+00:00 http://dev1.sol.com.au/paper/pyrexia-in-patients-treated-with-dabrafenib-plus-trametinib-across-clinical-trials-in-braf-mutant-cancers-2/ 2022-11-20T02:44:10+00:00 http://dev1.sol.com.au/paper/response-to-multicentre-selective-lymphadenectomy-trial-1-key-primary-data-remain-unavailable/ 2022-11-20T02:48:23+00:00 http://dev1.sol.com.au/paper/discussion-of-costs-and-financial-burden-in-clinical-practice-a-survey-of-medical-oncologists-in-australia/ 2022-11-20T02:54:33+00:00 http://dev1.sol.com.au/paper/combination-of-the-sting-agonist-miw815-and-pd-1-inhibitor-spartalizumab-in-advanced-metastatic-solid-tumors-or-lymphomas-an-open-label-multicenter-phase-ib-study/ 2022-11-20T03:01:27+00:00 http://dev1.sol.com.au/paper/utility-of-next-generation-sequencing-for-differentiating-malignant-pecoma-from-metastatic-melanoma/ 2022-11-20T03:08:23+00:00 http://dev1.sol.com.au/paper/sentinel-node-biopsy-linchpin-of-melanoma-management/ 2022-11-20T03:13:04+00:00 http://dev1.sol.com.au/paper/causes-consequences-and-clinical-significance-of-aneuploidy-across-melanoma-subtypes-2/ 2022-11-20T03:18:45+00:00 http://dev1.sol.com.au/paper/phase-1b-study-of-cobimetinib-plus-atezolizumab-in-patients-with-advanced-brafv600-wild-type-melanoma-progressing-on-prior-anti-programmed-death-1-therapy/ 2022-11-20T03:24:20+00:00 http://dev1.sol.com.au/paper/braf-inhibitor-cessation-prior-to-disease-progression-in-metastatic-melanoma-long-term-outcomes/ 2022-11-20T03:37:39+00:00 http://dev1.sol.com.au/paper/the-effect-of-organ-specific-tumor-microenvironments-on-response-patterns-to-immunotherapy/ 2022-11-20T03:43:45+00:00 http://dev1.sol.com.au/paper/which-strategies-support-the-effective-use-of-clinical-practice-guidelines-and-clinical-quality-registry-data-to-inform-health-service-delivery-a-systematic-review/ 2022-12-10T10:18:07+00:00 http://dev1.sol.com.au/paper/tertiary-lymphoid-structures-accompanied-by-fibrillary-matrix-morphology-impact-anti-tumor-immunity-in-basal-cell-carcinomas/ 2022-12-10T10:19:18+00:00 http://dev1.sol.com.au/paper/informing-a-position-statement-on-the-use-of-artificial-intelligence-in-dermatology-in-australia/ 2022-12-10T10:28:53+00:00 http://dev1.sol.com.au/paper/reflectance-confocal-microscopy-in-australia-perspectives-on-barriers-to-implementation-and-uptake/ 2022-12-10T10:33:50+00:00 http://dev1.sol.com.au/paper/toripalimab-vs-high-dose-interferon-%ce%b12b-as-adjuvant-therapy-for-resected-mucosal-melanoma/ 2022-12-10T10:40:04+00:00 http://dev1.sol.com.au/paper/five-year-survival-and-clinical-correlates-among-patients-with-advanced-non-small-cell-lung-cancer-melanoma-and-renal-cell-carcinoma-treated-with-immune-check-point-inhibitors-in-australian-tertiary/ 2022-12-10T10:45:50+00:00 http://dev1.sol.com.au/paper/metastasizing-and-non-metastasizing-thick-melanoma-clinicopathological-predictors-and-molecular-profiling/ 2022-12-10T11:01:22+00:00 http://dev1.sol.com.au/paper/talimogene-laherparepvec-monotherapy-for-head-and-neck-melanoma-patients/ 2023-01-21T10:54:51+00:00 http://dev1.sol.com.au/paper/melanomas-in-children-and-adolescents-clinicopathologic-features-and-survival-outcomes/ 2023-01-21T11:02:19+00:00 http://dev1.sol.com.au/paper/incorporating-carbon-into-health-care-adding-carbon-emissions-to-health-technology-assessments/ 2023-01-21T11:11:16+00:00 http://dev1.sol.com.au/paper/tumor-infiltrating-lymphocyte-therapy-or-ipilimumab-in-advanced-melanoma/ 2023-01-21T11:32:20+00:00 http://dev1.sol.com.au/paper/prognostic-significance-and-management-of-sentinel-nodes-in-the-triangular-intermuscular-space-of-patients-with-melanoma/ 2023-01-21T11:38:49+00:00 http://dev1.sol.com.au/paper/clinical-features-associated-with-outcomes-and-biomarker-analysis-of-dabrafenib-plus-trametinib-treatment-in-patients-with-braf-mutant-melanoma-brain-metastases/ 2023-01-21T11:57:07+00:00 http://dev1.sol.com.au/paper/revision-of-the-melanocytic-pathology-assessment-tool-and-hierarchy-for-diagnosis-classification-schema-for-melanocytic-lesions-a-consensus-statement/ 2023-04-03T00:14:47+00:00 http://dev1.sol.com.au/paper/talimogene-laherparepvec-in-combination-with-immunotherapy-a-viable-option/ 2023-04-03T00:20:26+00:00 http://dev1.sol.com.au/paper/genomic-and-proteomic-findings-in-early-melanoma-and-opportunities-for-early-diagnosis/ 2023-04-03T00:20:54+00:00 http://dev1.sol.com.au/paper/diagnostic-biopsies-of-suspected-skin-cancer-in-general-practice-from-2010-to-2017-in-victoria-australia/ 2023-04-03T00:21:11+00:00 http://dev1.sol.com.au/paper/representativeness-of-initial-skin-biopsies-showing-pure-desmoplastic-melanoma-implications-for-management/ 2023-04-03T00:30:41+00:00 http://dev1.sol.com.au/paper/perspectives-and-experiences-of-patient-led-melanoma-surveillance-using-digital-technologies-from-clinicians-involved-in-the-mel-self-pilot-randomized-controlled-trial-qualitative-interview-study/ 2023-05-14T00:58:25+00:00 http://dev1.sol.com.au/paper/biology-and-genetics-of-acquired-and-congenital-melanocytic-naevi/ 2023-05-14T01:07:21+00:00 http://dev1.sol.com.au/paper/efficacy-and-safety-of-immune-checkpoint-inhibitors-in-young-adults-with-metastatic-melanoma/ 2023-05-14T01:12:23+00:00 http://dev1.sol.com.au/paper/interobserver-agreement-in-the-histopathological-classification-of-desmoplastic-melanomas/ 2023-05-14T04:59:32+00:00 http://dev1.sol.com.au/paper/alternatives-and-reduced-need-for-sentinel-lymph-node-biopsy-slnb-staging-for-melanoma/ 2023-05-14T05:00:10+00:00 http://dev1.sol.com.au/paper/management-of-basal-cell-carcinoma-with-pulmonary-metastasis/ 2023-05-14T05:05:21+00:00 http://dev1.sol.com.au/paper/neo-adjuvant-immunotherapy-emerges-as-best-medical-practice-and-will-be-the-new-standard-of-care-for-macroscopic-stage-iii-melanoma/ 2023-05-14T05:08:22+00:00 http://dev1.sol.com.au/paper/author-correction-androgen-receptor-blockade-promotes-response-to-braf-mek-targeted-therapy/ 2023-05-14T05:15:25+00:00 http://dev1.sol.com.au/paper/interobserver-agreement-in-the-histopathological-classification-of-desmoplastic-melanomas-2/ 2023-05-14T05:19:25+00:00 http://dev1.sol.com.au/paper/hypercalcaemia-secondary-to-hypophysitis-and-cortisol-deficiency-another-immunotherapy-related-adverse-event/ 2023-05-14T05:23:22+00:00 http://dev1.sol.com.au/paper/genetics-and-genomics-of-melanoma-current-progress-and-future-directions/ 2023-05-14T05:27:17+00:00 http://dev1.sol.com.au/paper/genomic-profiling-of-metastatic-basal-cell-carcinoma-reveals-candidate-drivers-of-disease-and-therapeutic-targets/ 2023-05-14T05:31:46+00:00 http://dev1.sol.com.au/paper/survival-update-of-neoadjuvant-ipilimumab-plus-nivolumab-in-macroscopic-stage-iii-melanoma-in-the-opacin-and-opacin-neo-trials/ 2023-05-14T06:01:42+00:00 http://dev1.sol.com.au/paper/nivolumab-and-relatlimab-in-patients-with-advanced-melanoma-that-had-progressed-on-anti-programmed-death-1-programmed-death-ligand-1-therapy-results-from-the-phase-i-iia-relativity-020-trial/ 2023-05-14T06:06:01+00:00 http://dev1.sol.com.au/paper/association-of-germline-variants-in-telomere-maintenance-genes-pot1-terf2ip-acd-tert-with-spitzoid-morphology-in-familial-melanoma-a-multi-center-case-series/ 2023-05-14T06:36:38+00:00 http://dev1.sol.com.au/paper/ifn%ce%b3-signaling-sensitizes-melanoma-cells-to-bh3-mimetics/ 2023-05-14T06:40:18+00:00 http://dev1.sol.com.au/paper/plain-language-summary-development-and-validation-of-risk-calculators-for-people-with-thin-melanomas-on-their-skin-to-predict-the-likelihood-that-their-cancer-will-return/ 2023-05-14T06:44:45+00:00 http://dev1.sol.com.au/paper/durability-of-response-to-immune-checkpoint-inhibitors-in-metastatic-merkel-cell-carcinoma-after-treatment-cessation/ 2023-05-14T06:49:40+00:00 http://dev1.sol.com.au/paper/clinical-features-associated-with-outcomes-and-biomarker-analysis-of-dabrafenib-plus-trametinib-treatment-in-patients-with-braf-mutant-melanoma-brain-metastases-2/ 2023-05-14T06:54:39+00:00 http://dev1.sol.com.au/paper/longitudinal-trajectory-of-quality-of-life-for-patients-with-melanoma-brain-metastases-a-secondary-analysis-from-a-whole-brain-radiotherapy-randomized-clinical-trial/ 2023-05-14T07:00:47+00:00 http://dev1.sol.com.au/paper/adjuvant-radiotherapy-after-salvage-surgery-for-melanoma-recurrence-in-a-node-field-following-a-previous-lymph-node-dissection/ 2023-05-14T07:04:34+00:00 http://dev1.sol.com.au/paper/challenges-in-oncology-career-are-we-closing-the-gender-gap-results-of-the-new-esmo-women-for-oncology-committee-survey/ 2023-05-14T07:31:03+00:00 http://dev1.sol.com.au/paper/case-series-immune-checkpoint-inhibitor-induced-transverse-myelitis/ 2023-05-14T07:35:09+00:00 http://dev1.sol.com.au/paper/nicotinamide-for-skin-cancer-chemoprevention-in-transplant-recipients/ 2023-05-14T07:39:43+00:00 http://dev1.sol.com.au/paper/in-vivo-reflectance-confocal-microscopy-can-detect-the-invasive-component-of-lentigo-maligna-melanoma-prospective-analysis-and-case-control-study/ 2023-05-14T07:43:30+00:00 http://dev1.sol.com.au/paper/a-phase-i-trial-of-lxs196-a-protein-kinase-c-pkc-inhibitor-for-metastatic-uveal-melanoma/ 2023-05-14T07:46:58+00:00 http://dev1.sol.com.au/paper/lichen-sclerosus-and-immune-checkpoint-inhibitors-a-case-and-review-of-the-literature/ 2023-05-14T07:51:01+00:00 http://dev1.sol.com.au/paper/efficacy-and-toxicity-of-adjuvant-radiotherapy-in-recurrent-melanoma-after-adjuvant-immunotherapy/ 2023-05-14T07:55:27+00:00 http://dev1.sol.com.au/paper/rare-immune-related-adverse-events-in-patients-with-melanoma-incidence-spectrum-and-clinical-presentations/ 2023-05-14T07:58:28+00:00 http://dev1.sol.com.au/paper/surgical-outcomes-of-lymph-node-dissections-for-stage-iii-melanoma-after-neoadjuvant-systemic-therapy-are-not-inferior-to-upfront-surgery/ 2023-05-14T08:55:39+00:00 http://dev1.sol.com.au/paper/clinical-features-and-outcomes-of-cardiac-involvement-in-patients-with-cancer-treated-with-immune-checkpoint-inhibitors/ 2023-05-14T09:23:51+00:00 http://dev1.sol.com.au/paper/ifn-%ce%b3-signature-enables-selection-of-neoadjuvant-treatment-in-patients-with-stage-iii-melanoma/ 2023-05-14T09:44:01+00:00 http://dev1.sol.com.au/paper/lentigo-maligna-lentigo-maligna-melanoma-in-young-patients-in-australian-tertiary-centres/ 2023-05-14T09:48:17+00:00 http://dev1.sol.com.au/paper/has-the-advent-of-modern-adjuvant-systemic-therapy-for-melanoma-rendered-sentinel-node-biopsy-unnecessary/ 2023-05-14T10:01:30+00:00 http://dev1.sol.com.au/paper/the-molecular-and-functional-landscape-of-resistance-to-immune-checkpoint-blockade-in-melanoma/ 2023-05-14T10:06:52+00:00 http://dev1.sol.com.au/paper/time-to-reconsider-the-role-of-sentinel-lymph-node-biopsy-in-melanoma/ 2023-05-14T10:21:10+00:00 http://dev1.sol.com.au/paper/neoadjuvant-relatlimab-and-nivolumab-for-resectable-melanoma/ 2023-05-15T02:01:22+00:00 http://dev1.sol.com.au/paper/reply-to-a-mangla-and-e-hindie/ 2023-05-15T03:34:42+00:00 http://dev1.sol.com.au/paper/embedding-electronic-patient-reported-outcome-measures-into-routine-care-for-patients-with-stage-iii-melanoma-eproms-mel-protocol-for-a-prospective-longitudinal-mixed-methods-pilot-study/ 2023-05-15T03:41:18+00:00 http://dev1.sol.com.au/paper/health-related-quality-of-life-with-nivolumab-plus-relatlimab-versus-nivolumab-monotherapy-in-patients-with-previously-untreated-unresectable-or-metastatic-melanoma-relativity-047-trial/ 2023-05-15T08:07:21+00:00 http://dev1.sol.com.au/paper/spatial-mapping-reveals-granuloma-diversity-and-histopathological-superstructure-in-human-tuberculosis/ 2023-05-15T09:36:53+00:00 http://dev1.sol.com.au/paper/overall-survival-and-response-with-nivolumab-and-relatlimab-in-advanced-melanoma/ 2023-05-15T09:45:14+00:00 http://dev1.sol.com.au/paper/risk-of-developing-a-second-primary-melanoma-after-a-first-primary-melanoma-in-a-population-based-australian-cohort/ 2023-05-15T09:50:56+00:00 http://dev1.sol.com.au/paper/junctional-nevus-and-early-melanoma-on-sun-damaged-skin-of-the-head-neck-a-clinico-pathologic-challenge/ 2023-05-15T09:55:10+00:00 http://dev1.sol.com.au/paper/reply-to-msjaad-d-23-00002r1/ 2023-05-15T10:05:54+00:00 http://dev1.sol.com.au/paper/a-sheep-in-wolfs-clothing-agminated-blue-naevi-masquerading-as-in-transit-melanoma-metastases/ 2023-05-15T10:15:26+00:00 http://dev1.sol.com.au/paper/intratumoral-cd16-macrophages-are-associated-with-clinical-outcomes-of-patients-with-metastatic-melanoma-treated-with-combination-anti-pd-1-and-anti-ctla-4-therapy/ 2023-05-15T10:22:46+00:00 http://dev1.sol.com.au/paper/mc1r-r-allele-does-not-increase-melanoma-risk-in-mitf-e318k-carriers/ 2023-05-15T10:42:49+00:00 http://dev1.sol.com.au/paper/role-of-reflectance-confocal-microscopy-for-in-vivo-investigation-of-oral-disorders-white-red-and-pigmented-lesions/ 2023-05-15T10:49:52+00:00 http://dev1.sol.com.au/paper/aso-visual-abstract-prognostic-significance-and-management-of-sentinel-nodes-in-the-triangular-intermuscular-space-of-patients-with-melanoma/ 2023-05-15T10:55:49+00:00 http://dev1.sol.com.au/paper/biology-and-genetics-of-acquired-and-congenital-melanocytic-naevi-2/ 2023-05-15T11:02:50+00:00 http://dev1.sol.com.au/paper/efficacy-of-ipilimumab-3mn-kg-following-progression-on-low-dose-ipilimumab-in-metastatic-melanoma/ 2023-05-15T11:13:35+00:00 http://dev1.sol.com.au/paper/human-genetics-society-of-australasia-position-statement-use-of-polygenic-scores-in-clinical-practice-and-population-health-twin-res-hum-genet/ 2023-05-15T11:18:31+00:00 http://dev1.sol.com.au/paper/measuring-the-quality-of-skin-cancer-management-in-primary-care-a-scoping-review/ 2023-05-15T11:21:59+00:00 http://dev1.sol.com.au/paper/systemic-lrg1-expression-in-melanoma-is-associated-with-disease-progression-and-recurrence/ 2023-05-15T11:28:45+00:00 http://dev1.sol.com.au/paper/author-correction-reversal-of-pre-existing-ngfr-driven-tumor-and-immune-therapy-resistance/ 2023-05-15T11:32:50+00:00 http://dev1.sol.com.au/paper/common-toxicities-associated-with-immune-checkpoint-inhibitors-and-targeted-therapy-in-the-treatment-of-melanoma-a-systematic-scoping-review/ 2023-05-15T11:38:39+00:00 http://dev1.sol.com.au/paper/aso-visual-abstract-is-a-history-of-optimal-staging-by-slnb-in-the-era-prior-to-adjuvant-therapy-associated-with-improved-outcome-once-melanoma-patients-have-progressed-to-advanced-disease/ 2023-05-15T11:52:04+00:00 http://dev1.sol.com.au/paper/chemotherapy-in-cutaneous-melanoma-is-there-still-a-role/ 2023-05-15T11:56:24+00:00 http://dev1.sol.com.au/paper/study-protocol-for-a-randomised-controlled-trial-to-evaluate-the-use-of-melanoma-surveillance-photography-to-the-improve-early-detection-of-melanoma-in-ultra-high-and-high-risk-patients-the-image-tri/ 2023-05-15T12:05:53+00:00 http://dev1.sol.com.au/paper/cutaneous-melanoma/ 2023-08-16T01:29:16+00:00 http://dev1.sol.com.au/paper/towards-modulating-the-gut-microbiota-to-enhance-the-efficacy-of-immune-checkpoint-inhibitors/ 2024-05-09T00:38:40+00:00 https://dev1.sol.com.au/wp-content/uploads/2023/07/RS-1.jpg https://dev1.sol.com.au/wp-content/uploads/2023/07/RS2.jpg http://dev1.sol.com.au/paper/development-and-validation-of-a-novel-model-to-predict-recurrence-free-survival-and-melanoma-specific-survival-after-sentinel-lymph-node-biopsy-in-patients-with-melanoma-an-international-retrospecti/ 2024-05-09T02:04:57+00:00 http://dev1.sol.com.au/paper/a-review-of-skin-cancer-primary-prevention-activities-in-primary-care-settings/ 2024-05-09T02:10:38+00:00 http://dev1.sol.com.au/paper/pembrolizumab-versus-placebo-as-adjuvant-therapy-in-resected-stage-iib-or-iic-melanoma-outcomes-in-histopathologic-subgroups-from-the-randomized-double-blind-phase-3-keynote-716-trial/ 2024-05-09T02:13:11+00:00 http://dev1.sol.com.au/paper/melanotransferrin-functions-as-a-pro-oncogenic-wnt-agonist-a-yin-yang-relationship-in-melanoma-with-the-wnt-antagonist-and-metastasis-suppressor-ndrg1/ 2024-05-09T02:17:43+00:00 http://dev1.sol.com.au/paper/predicting-recurrence-free-and-overall-survival-for-patients-with-stage-ii-melanoma-the-mia-calculator/ 2024-05-09T05:46:38+00:00 http://dev1.sol.com.au/paper/multiomics-analysis-reveals-a-type-iii-driven-immune-response-in-immunotherapy-induced-toxicity-in-melanoma-and-identifies-potential-new-therapeutic-targets/ 2024-05-09T06:16:51+00:00 http://dev1.sol.com.au/paper/cancer-in-general-practice-research-priorities-in-australia/ 2024-05-09T07:00:13+00:00 http://dev1.sol.com.au/paper/anti-pd-l1-plus-braf-mek-inhibitors-triplet-therapy-after-failure-of-immune-checkpoint-inhibition-and-targeted-therapy-in-patients-with-advanced-melanoma/ 2024-06-03T05:46:56+00:00 http://dev1.sol.com.au/paper/commentary-real-world-post-deployment-performance-of-a-novel-machine-learning-based-digital-health-technology-for-skin-lesion-assessment-and-suggestions-for-post-market-surveillance/ 2024-06-03T06:06:40+00:00 http://dev1.sol.com.au/paper/stroma-infiltrating-t-cell-spatiotypes-define-immunotherapy-outcomes-in-adolescent-and-young-adult-patients-with-melanoma/ 2024-06-03T07:11:35+00:00 http://dev1.sol.com.au/paper/prognostic-and-predictive-biomarkers-in-head-and-neck-cancer-something-old-something-new-something-borrowed-something-blue-and-a-sixpence-in-your-shoe/ 2024-06-03T07:22:07+00:00 http://dev1.sol.com.au/paper/the-impact-of-next-generation-sequencing-on-interobserver-agreement-and-diagnostic-accuracy-of-desmoplastic-melanocytic-neoplasms/ 2024-06-13T06:07:01+00:00 http://dev1.sol.com.au/paper/implementation-considerations-for-risk-tailored-cancer-screening-in-the-population-a-scoping-review/ 2024-06-13T06:11:42+00:00 http://dev1.sol.com.au/paper/baseline-ultrasound-and-fdg-pet-ct-imaging-in-merkel-cell-carcinoma/ 2025-08-01T07:12:01+00:00